KLRS Q3 2025 Earnings — Kalaris Therapeutics Inc Revenue & Financial Results | Market Cap Arena

KLRSKalaris Therapeutics Inc

$187M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$13M

Net Income

-$12M

EPS (Diluted)

$-0.64

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$12M

Stock-Based Comp.

$638,000

Balance Sheet

Total Assets

$81M

Total Liabilities

$39M

Stockholders' Equity

$42M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$13M	-$38M	+66.3%
Net Income	-$12M	-$38M	+68.8%